|12 Months Ended|
Dec. 31, 2017
|Subsequent Events [Abstract]|
Since December 31, 2017, the Company granted 701,339 stock options to officers and other employees.
On February 5, 2018, the Company and NEXT BT Co. Ltd., the successor in interest to Rexgene, terminated the research collaboration agreement between the Company and Rexgene. In exchange for Next-BT terminating its rights to RX-0201 in Asia, the Company agreed to pay Next-BT a royalty in the low single digits of any net sales of RX-0201 the Company makes in Asia and 50% of the Company’s licensing revenue related to licensing of RX-0201 in Asia, up to an aggregate of $5,000,000.
On February 8, 2018, the Company entered into a research and development collaboration agreement with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) under which Haichang will develop a nano-liposomal formulation of RX-0201 using its proprietary QTzomes™ technology and will conduct certain pre-clinical and clinical activities through completion of a Phase 2a proof-of-concept clinical study in hepatocellular carcinoma in China.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
No definition available.